retrograde method (a built-in feature of simcyp) (Simcyp)
90
Structured Review
Simcyp
retrograde method (a built-in feature of simcyp)
Retrograde Method (A Built In Feature Of Simcyp), supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+built-in+method/retrograde+method/pm34196005-51-32-38
Average 90 stars, based on 1 article reviews
Retrograde Method (A Built In Feature Of Simcyp), supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+built-in+method/retrograde+method/pm34196005-51-32-38
Average 90 stars, based on 1 article reviews
retrograde method (a built-in feature of simcyp) - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Binding Assay:Article Title: Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A Article Snippet: Parameters Initial Optimized Population Sim-Healthy Volunteers Sim-Healthy Volunteers Minimum Age (years) 24 24 Maximum Age (years) 53 53 Proportion of females 0 0 fa 1 1 fg 0.9 0.9 fCLBile(%) 7 7 CLadd (L/h) 1.243 0 %HEPCL CYP3A4 37% 61% %HEPCL CYP2J2 29% 5% fa: fraction absorbed from gut, fg: fraction escaping the metabolism in enterocyte, fCLBile: fraction of biliary clearance on overall clearance, CLadd: additional systemic clearance, %HEPCL: percentage in hepatic clearance Table S2-4 Input parameters of the rivaroxaban PBPK model Sample parameter Value Assumption(s) and references Physicochemical properties and blood binding Compound type Neutral 5 Molecular weight 435.88 5 Log P 1.5 5 B/P ratio 0.71 5 fu 0.065 5 Plasma binding protein HSA 5 Absorption Absorption model ADAM fu,Gut 0.209 Calculated with Molecular Weight:Article Title: Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A Article Snippet: Parameters Initial Optimized Population Sim-Healthy Volunteers Sim-Healthy Volunteers Minimum Age (years) 24 24 Maximum Age (years) 53 53 Proportion of females 0 0 fa 1 1 fg 0.9 0.9 fCLBile(%) 7 7 CLadd (L/h) 1.243 0 %HEPCL CYP3A4 37% 61% %HEPCL CYP2J2 29% 5% fa: fraction absorbed from gut, fg: fraction escaping the metabolism in enterocyte, fCLBile: fraction of biliary clearance on overall clearance, CLadd: additional systemic clearance, %HEPCL: percentage in hepatic clearance Table S2-4 Input parameters of the rivaroxaban PBPK model Sample parameter Value Assumption(s) and references Physicochemical properties and blood binding Compound type Neutral 5 Molecular weight 435.88 5 Log P 1.5 5 B/P ratio 0.71 5 fu 0.065 5 Plasma binding protein HSA 5 Absorption Absorption model ADAM fu,Gut 0.209 Calculated with Clinical Proteomics:Article Title: Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A Article Snippet: Parameters Initial Optimized Population Sim-Healthy Volunteers Sim-Healthy Volunteers Minimum Age (years) 24 24 Maximum Age (years) 53 53 Proportion of females 0 0 fa 1 1 fg 0.9 0.9 fCLBile(%) 7 7 CLadd (L/h) 1.243 0 %HEPCL CYP3A4 37% 61% %HEPCL CYP2J2 29% 5% fa: fraction absorbed from gut, fg: fraction escaping the metabolism in enterocyte, fCLBile: fraction of biliary clearance on overall clearance, CLadd: additional systemic clearance, %HEPCL: percentage in hepatic clearance Table S2-4 Input parameters of the rivaroxaban PBPK model Sample parameter Value Assumption(s) and references Physicochemical properties and blood binding Compound type Neutral 5 Molecular weight 435.88 5 Log P 1.5 5 B/P ratio 0.71 5 fu 0.065 5 Plasma binding protein HSA 5 Absorption Absorption model ADAM fu,Gut 0.209 Calculated with Permeability:Article Title: Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A Article Snippet: Parameters Initial Optimized Population Sim-Healthy Volunteers Sim-Healthy Volunteers Minimum Age (years) 24 24 Maximum Age (years) 53 53 Proportion of females 0 0 fa 1 1 fg 0.9 0.9 fCLBile(%) 7 7 CLadd (L/h) 1.243 0 %HEPCL CYP3A4 37% 61% %HEPCL CYP2J2 29% 5% fa: fraction absorbed from gut, fg: fraction escaping the metabolism in enterocyte, fCLBile: fraction of biliary clearance on overall clearance, CLadd: additional systemic clearance, %HEPCL: percentage in hepatic clearance Table S2-4 Input parameters of the rivaroxaban PBPK model Sample parameter Value Assumption(s) and references Physicochemical properties and blood binding Compound type Neutral 5 Molecular weight 435.88 5 Log P 1.5 5 B/P ratio 0.71 5 fu 0.065 5 Plasma binding protein HSA 5 Absorption Absorption model ADAM fu,Gut 0.209 Calculated with Formulation:Article Title: Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A Article Snippet: Parameters Initial Optimized Population Sim-Healthy Volunteers Sim-Healthy Volunteers Minimum Age (years) 24 24 Maximum Age (years) 53 53 Proportion of females 0 0 fa 1 1 fg 0.9 0.9 fCLBile(%) 7 7 CLadd (L/h) 1.243 0 %HEPCL CYP3A4 37% 61% %HEPCL CYP2J2 29% 5% fa: fraction absorbed from gut, fg: fraction escaping the metabolism in enterocyte, fCLBile: fraction of biliary clearance on overall clearance, CLadd: additional systemic clearance, %HEPCL: percentage in hepatic clearance Table S2-4 Input parameters of the rivaroxaban PBPK model Sample parameter Value Assumption(s) and references Physicochemical properties and blood binding Compound type Neutral 5 Molecular weight 435.88 5 Log P 1.5 5 B/P ratio 0.71 5 fu 0.065 5 Plasma binding protein HSA 5 Absorption Absorption model ADAM fu,Gut 0.209 Calculated with Solubility:Article Title: Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A Article Snippet: Parameters Initial Optimized Population Sim-Healthy Volunteers Sim-Healthy Volunteers Minimum Age (years) 24 24 Maximum Age (years) 53 53 Proportion of females 0 0 fa 1 1 fg 0.9 0.9 fCLBile(%) 7 7 CLadd (L/h) 1.243 0 %HEPCL CYP3A4 37% 61% %HEPCL CYP2J2 29% 5% fa: fraction absorbed from gut, fg: fraction escaping the metabolism in enterocyte, fCLBile: fraction of biliary clearance on overall clearance, CLadd: additional systemic clearance, %HEPCL: percentage in hepatic clearance Table S2-4 Input parameters of the rivaroxaban PBPK model Sample parameter Value Assumption(s) and references Physicochemical properties and blood binding Compound type Neutral 5 Molecular weight 435.88 5 Log P 1.5 5 B/P ratio 0.71 5 fu 0.065 5 Plasma binding protein HSA 5 Absorption Absorption model ADAM fu,Gut 0.209 Calculated with |